Inadequate responders to osteoporosis treatment: proposal for an operational definition
- First Online:
The concept of inadequate response to osteoporosis treatment is not clear. In the literature several criteria have been used. We propose an operational definition of an inadequate responder based on the changes observed in bone mineral density and incident fractures while on therapy.
Fractures may occur in compliant patients even while on active treatment. These cases have been defined as inadequate responders (IR).
We reviewed the basis for this concept and propose an operational definition for IR.
Good compliance and adequate calcium and vitamin D supplementation are the first requirement. The second requirement is a treatment period of at least 1 year, since before that time treatment may not have been fully effective. Fractures are the gold standard for measuring efficacy and changes in bone density and turnover markers may be surrogates. We propose classifying patient response as: Inadequate—incident fracture and a decrease in BMD greater than a significant change (Trend Assessment Margin or TAM); Possibly inadequate—incident fracture or a decrease in BMD greater than a significant change (TAM); and Appropriate—no fracture and no decrease in BMD greater than a significant change (TAM). Additional criteria (biochemical markers, bone quality parameters) may be taken into account.
A wide consensus on the IR concept is required given its clinical, regulatory, and reimbursement implications.
KeywordsBMD Fracture Osteoporosis Treatment Treatment response
- 5.Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352CrossRefPubMedGoogle Scholar
- 6.Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMedGoogle Scholar
- 11.Hugen PW, Langebeek N, Burger DM et al (2002) Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 30:324–334CrossRefPubMedGoogle Scholar
- 17.Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468CrossRefPubMedGoogle Scholar
- 19.Dempster DW (2002) Bone remodeling. In: Coe FL, Favus MJ (eds) (2002) Disorders of bone and mineral metabolism, 2nd edn. Lippincott Williams and Wilkins, Baltimore, pp 315–343Google Scholar
- 37.National Institute for Clinical Excellence (2004) Final appraisal determination—secondary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.nice.org.uk/page.aspx?o=115560
- 39.Obermayer-Pietsch BM, Nickelsen T, Marin F et al (2006) Response of BMD to 24 months of teriparatide (rhPTH 1–34) in patients with and without prior antiresorptive treatment: final results from the EUROFORS Study. J Bone Miner Res 21 [Suppl 1]:S43Google Scholar
- 47.Tofteng CL, Abrahamsen B, Jensen JE et al (2004) Two single nucleotide polymorphisms in the CYP17 and COMT Genes—relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study. Calcif Tissue Int 75:123–132CrossRefPubMedGoogle Scholar
- 49.Steines D, Arnaud C, Liew S et al (2005) Predicting hip fracture in a sub-group of subjects from the study of osteoporotic fractures using automated structural measurements of proximal femur in pelvic radiographs. J Bone Miner Res 20 [Suppl 1]:F090Google Scholar